Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Morphic Holding, Inc. (MORF)  
$30.80 3.04 (10.95%) as of 4:30 Fri 5/24


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 49,740,000
Market Cap: 1.53(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $19.95 - $62.11
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Morphic is a biopharmaceutical company. Co. is applying its proprietary insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with various approved injectable blockbuster drugs for the treatment of chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. Co. is developing its pipeline, including its main product candidate, MORF-057, an a4ss7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease. Co. has also developed selective oral avss6-specific integrin inhibitors including MORF-720 and MORF-627.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 4,776 1,054,776
Total Buy Value $0 $0 $98,239 $47,348,239
Total People Bought 0 0 2 3
Total Buy Transactions 0 0 2 3
Total Shares Sold 0 35,876 75,263 317,833
Total Sell Value $0 $986,256 $3,207,660 $15,087,539
Total People Sold 0 5 5 5
Total Sell Transactions 0 5 11 29
End Date 2024-02-25 2023-11-24 2023-05-26 2022-05-26

   
Records found: 366
  Page 14 of 15  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Devaul William General Counsel and Secretary   •       –      –    2020-07-07 4 OE $4.32 $5,448 D/D 1,261 3,761     -
   Lugovskoy Alexey Chief Development Officer   •       –      –    2020-07-07 4 AS $25.74 $129,265 D/D (5,001) 109,391 18%     
   Devaul William General Counsel and Secretary   •       –      –    2020-07-06 4 AS $25.88 $56,934 D/D (2,200) 2,500 15%     
   Devaul William General Counsel and Secretary   •       –      –    2020-07-06 4 OE $4.32 $9,504 D/D 2,200 4,700     -
   Lugovskoy Alexey Chief Development Officer   •       –      –    2020-07-06 4 AS $25.87 $111,344 D/D (4,304) 114,392 15%     
   Devaul William General Counsel and Secretary   •       –      –    2020-07-02 4 AS $26.51 $143,133 D/D (5,400) 2,500 14%     
   Devaul William General Counsel and Secretary   •       –      –    2020-07-02 4 OE $4.32 $23,328 D/D 5,400 7,900     -
   Lugovskoy Alexey Chief Development Officer   •       –      –    2020-07-02 4 AS $26.47 $265,734 D/D (10,039) 118,696 14%     
   Devaul William General Counsel and Secretary   •       –      –    2020-07-01 4 AS $26.15 $60,533 D/D (2,283) 2,500 15%     
   Devaul William General Counsel and Secretary   •       –      –    2020-07-01 4 OE $4.32 $9,863 D/D 2,283 4,783     -
   Lugovskoy Alexey Chief Development Officer   •       –      –    2020-07-01 4 AS $26.18 $119,790 D/D (4,513) 128,735 15%     
   Rogers Bruce Chief Scientific Officer   •       –      –    2020-06-10 4 S $23.18 $583,251 D/D (25,000) 153,319 -14%     
   Farrell Robert E Jr SVP Finance and CAO   •       –      –    2020-06-01 4 S $20.35 $135,972 D/D (6,681) 77,934 -32%     
   Farrell Robert E Jr SVP Finance and CAO   •       –      –    2020-05-29 4 S $20.17 $268,672 D/D (13,319) 84,615 -22%     
   Rogers Bruce Chief Scientific Officer   •       –      –    2020-05-28 4 S $22.29 $450,914 D/D (20,000) 178,319 -21%     
   Schegerin Marc CFO and COOOfficer   •       –      –    2020-04-06 3 IO $0.00 $0 D/D 0 2,000 74%     
   Glaxosmithkline Plc Director   –       •      –    2019-07-01 4 B $15.00 $4,999,995 I/I 333,333 2,633,772 2.1     -
   Glaxosmithkline Plc Director   –       •      –    2019-07-01 4 A $0.00 $0 I/I 2,300,439 2,300,439     -
   Slattery Joseph P Director   –       •      –    2019-07-01 4 B $15.00 $100,005 D/D 6,667 6,667 2.39     -
   Stampacchia Otello Director   –       •       •   2019-07-01 4 B $15.00 $1,999,995 I/I 133,333 2,969,582 2.25     -
   Stampacchia Otello Director   –       •       •   2019-07-01 4 A $0.00 $0 I/I 2,836,249 2,836,249     -
   Stampacchia Otello Director   –       •       •   2019-07-01 4 B $15.00 $1,999,995 D/D 133,333 2,969,582 3.92     -
   Stampacchia Otello Director   –       •       •   2019-07-01 4 A $0.00 $0 D/D 2,836,249 2,836,249     -
   Springer Timothy A Director   –       •       •   2019-07-01 4 B $15.00 $499,995 I/I 33,333 375,019 2.25     -
   Springer Timothy A Director   –       •       •   2019-07-01 4 A $0.00 $0 I/I 341,686 341,686     -
  366 Records found
  Previous  10  11  12  13  14  15   
  Page 14 of 15
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us